semaglutide vs tirzepatide cardiovascular 💉 In a large real-world study, was associated with a lower incidence of major outcomes semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart Tirzepatide versus Semaglutide Once Weekly

Human Reproduction Update, 30(1), 6785

Sleep quality improvement Sleep problems are one of the most underreported side effects of weight loss in general and GLP-1 therapy specifically

Typical dosing progression may include: 0.25 mg once weekly 0.5 mg once weekly 1 mg once weekly 1.7 mg once weekly 2.4 mg once weekly (maintenance dose) Safety Information & Precautions Before using Wegovy, inform your healthcare provider if you have: History of thyroid cancer Multiple endocrine neoplasia syndrome type 2 Pancreatitis history Gallbladder disease Kidney disease Severe gastrointestinal conditions Important safety considerations include: Use under medical supervision Follow the prescribed dosing schedule Do not exceed recommended dosage Monitor for unusual symptoms Higher-dose semaglutide therapy such as Wegovy FlexTouch Pen 1.7 Mg may be used within advanced weight-management treatment plans

So what happens when your medication has lost 20%, 40%, or even 60% of its potency

Retatrutide remains an investigational compound and is not approved for human use in any jurisdiction as of this writing

Eur J Med Res 1997;2:37-43